Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

Experts discussed the challenges of managing GPP and highlight a pivotal study on the subcutaneous formulation of spesolimab, demonstrating its potential to prevent GPP flares and improve patient outcomes despite some limitations.

Fighting the Flare of GPP: Expert Insights on Spesolimab

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

In a meta-analysis of over 61 million participants, it was found that AD patients have a 37% risk of developing IBD and similar conditions.

Patients with Atopic Dermatitis Are More Susceptible to Developing Inflammatory Bowel Disease

The latest publication from OJM Group provides 7 core strategies for dermatologists looking to meet their financial goals.

Wealth Strategies for Today’s Physician: David Mandell, JD, MBA, Shares Insights from New Playbook

Jackson discusses EVO756, a promising MRGPRX2 antagonist targeting mast cells to treat chronic inflammatory diseases like spontaneous urticaria.

Exploring EVO756 in Chronic Inflammatory Disease Treatment: Q&A with Evommune's Mark Jackson, MD

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

Experience the ultimate behind-the-scenes round table discussion, as key opinion leaders provide exclusive insights and highlight key takeaways from their impactful presentations, only days after a conference takes place.

1rem

Enhancing Patient Outcomes: Topical Therapy for  Corticosteroid-Responsive Dermatoses

Learn more about the in-depth topics covered in the November 2023 Frontline Forum corticosteroid-responsive dermatoses supplement of Dermatology Times.

Discovering Dermatology Times: November 2023 Corticosteroid-Responsive Dermatoses Supplement

Experts discuss enhancing patient outcomes, comparing clobetasol cream concentrations, and more.

Frontline Forum Part 3: Topical Therapy for Corticosteroid-Responsive Dermatoses

Experts discuss enhancing patient outcomes, topical formulations and epidermal barrier dysfunction, and more.

Frontline Forum Part 2: Topical Therapy for Corticosteroid-Responsive Dermatoses

Experts discuss enhancing patient outcomes, the "mounting mutiny" against topicals, and more.

Frontline Forum Part 1: Topical Therapy for Corticosteroid-Responsive Dermatoses

Enhancing Patient Outcomes: Topical Therapy for Corticosteroid-Responsive Dermatoses | articles